Pharmacogenomics & Personalized Medication Management in Geriatric Psychiatry: A Systematic Review

Introduction

In the realm of geriatric psychiatry, the management of depression presents a unique set of challenges. Elderly patients often contend with not only the complexities of their mental health but also a myriad of physical ailments and medication regimens. Addressing these challenges necessitates a tailored approach that recognizes the individuality of each patient. This systematic review delves into the emerging field of pharmacogenomic and personalized medication management in geriatric psychiatry, specifically focusing on depression. By evaluating a collection of studies, we aim to explore the significance of personalized care, the integration of genetic insights, and the utility of pharmacogenomic strategies in enhancing treatment outcomes for elderly individuals grappling with depression.

Methods

A systematic review was conducted using three databases (PubMed, Cochrane Library, and Embase) to identify the relevant articles published in the english language from 2010 - 2023.Inclusion Criteria focused on:-Individuals aged 60 years or older receiving psychiatric Care (WHO*)-Studies that investigate the use of pharmacogenomics or genetic testing to inform medication selection, dosing, or treatment decisions in geriatric psychiatry-Studies reporting relevant outcomes such as medication efficacy, adverse drug reactions, treatment response, quality of life, cognitive function, or other patient-centered outcomes in geriatric psychiatric patients-Studies included are observational and experimental studies.

Results

The studies under scrutiny collectively underscore the paramount importance of individualized care for geriatric patients battling depression. It becomes evident that a one-size-fits-all approach is ill-suited to address the intricacies of this population's mental and physical health. The inclusion of genetic insights, mainly through pharmacogenomic testing, emerges as a promising avenue. Studies such as those examining the serotonin transporter gene polymorphism and antidepressant response (Green Murphy) or pharmacogenetic screening for CYP2D6 (Berm and Schans) demonstrate the practical application of genetic data to inform treatment decisions and reduce the risk of adverse drug reactions. Furthermore, research such as Combinatorial Pharmacogenomic Testing for Older Adults with Depression (Forester) and Integration of a Pharmacist-Led Pharmacogenomic Service in a Geriatric Clinic (Kehr) underscore the potential for personalized approaches to elevate treatment outcomes. Cumulatively, these findings suggest that personalized medication management can significantly enhance the quality of life for elderly patients battling depression by optimizing treatment efficacy and minimizing adverse effects.

Conclusions

In conclusion, the systematic review of studies centered on pharmacogenomic and personalized medication management in geriatric psychiatry, with a specific focus on depression, highlights a promising avenue for improving the care of elderly patients. These studies emphasize the necessity of personalized care, accounting for genetic variations, comorbid conditions, and cognitive status. While not all studies unanimously endorse pharmacogenomic strategies, they collectively underscore the potential utility of genetic insights in optimizing treatment outcomes. The path ahead involves continued research, collaboration between clinicians, researchers, and pharmacists, and the integration of genetic information into clinical practice to ensure that every elderly patient receives tailored and effective treatment based on their unique genetic profile. In the realm of geriatric psychiatry, the future holds the promise of more effective, safer, and personalized treatments for depression, ultimately enhancing the well-being of our elderly population.